M7-FLIPI Not Valid in Follicular Lymphoma Patients with First-Line Rituximab Chemo-Free Therapy

被引：1
|
作者：
Lockmer, Sandra [1 ,2 ]
Ren, Weicheng [3 ]
Ostenstad, Bjorn [4 ]
Brodtkorb, Marianne [5 ]
Wahlin, Bjorn E. [6 ,7 ,8 ]
Pan-Hammarstrom, Qiang [9 ]
Kimby, Eva [10 ]
机构：
[1] Karolinska Inst, Dept Internal Med, Stockholm, Sweden
[2] Karolinska Univ Hosp, Dept Hematol, Stockholm, Sweden
[3] Karolinska Inst, Dept Biosci & Nutr, Huddinge, Sweden
[4] Oslo Univ Hosp, Oslo, Norway
[5] Oslo Univ Hosp, Dept Oncol, Oslo, Norway
[6] Karolinska Univ Hosp, Dept Hematol, Solna, Sweden
[7] Karolinska Inst, Dept Med Huddinge, Stockholm, Sweden
[8] Karolinska Univ Hosp, Stockholm, Sweden
[9] Karolinska Inst, Dept Biosci & Nutr, Stockholm, Sweden
[10] Karolinska Inst, Hematol, Stockholm, Sweden
来源：
BLOOD | 2018年 / 132卷
关键词：
D O I：
10.1182/blood-2018-99-117949
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
4154
引用
收藏
页数：3
相关论文
共 50 条
  • [41] Cost-Effectiveness Analysis of Bendamustine Plus Rituximab as a First-Line Treatment for Patients with Follicular Lymphoma in Spain
    Sabater, Eliazar
    Lopez-Guillermo, Armando
    Rueda, Antonio
    Salar, Antonio
    Oyaguez, Itziar
    Manuel Collar, Juan
    APPLIED HEALTH ECONOMICS AND HEALTH POLICY, 2016, 14 (04) : 465 - 477
  • [42] Rituximab as first-line and maintenance therapy for patients with indolent non-Hodgkin's lymphoma
    Hainsworth, JD
    Litchy, S
    Burris, HA
    Scullin, DC
    Corso, SW
    Yardley, DA
    Morrissey, L
    Greco, FA
    JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (20) : 4261 - 4267
  • [43] Evaluation of the m7-FLIPI in Patients with Follicular Lymphoma Treated within the Gallium Trial: EZH2 mutation Status May be a Predictive Marker for Differential Efficacy of Chemotherapy
    Jurinovic, Vindi
    Passerini, Verena
    Oestergaard, Mikkel Z.
    Knapp, Andrea
    Mundt, Kirsten
    Araf, Shamzah
    Richter, Julia
    Fitzgibbon, Jude
    Klapper, Wolfram
    Marcus, Robert E.
    Davies, Andrew
    Herold, Michael
    Hiddemann, Wolfgang
    Unterhalt, Michael
    Hoster, Eva
    Weigert, Oliver
    BLOOD, 2019, 134
  • [44] A randomized trial of fludarabine and mitoxantrone plus rituximab versus CHOP plus rituximab as first-line treatment in patients with follicular lymphoma.
    Zinzani, PL
    BLOOD, 2001, 98 (11) : 842A - 842A
  • [45] Rituximab as first-line monotherapy in low-grade follicular lymphoma with a low tumor burden
    Solal-Céligny, P
    ANTI-CANCER DRUGS, 2001, 12 : S11 - S14
  • [46] Primary nodal follicular lymphoma with secondary cutaneous manifestations. First-line rituximab monotherapy
    Koch, R.
    Sander, C. A.
    HAUTARZT, 2010, 61 (11): : 976 - 979
  • [47] CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma
    Marcus, R
    Imrie, K
    Belch, A
    Cunningham, D
    Flores, E
    Catalano, J
    Solal-Celigny, P
    Offner, F
    Walewski, J
    Raposo, J
    Jack, A
    Smith, P
    BLOOD, 2005, 105 (04) : 1417 - 1423
  • [48] Cost-Effectiveness Analysis of Maintenance Therapy with Rituximab in Patients with Follicular Lymphoma Responding to Induction Therapy at the First Line
    Castro Gomez, Antonio J.
    Lopez-Guillermo, Armando
    Rueda Dominguez, Antonio
    Salar, Antonio
    Varela Moreno, Cristina
    Rubio-Terres, Carlos
    REVISTA ESPANOLA DE SALUD PUBLICA, 2012, 86 (02): : 163 - 176
  • [49] COST-EFFECTIVENESS ANALYSIS OF RITUXIMAB MAINTENANCE TREATMENT OF FOLLICULAR LYMPHOMA IN PATIENTS RESPONDING TO FIRST-LINE INMUNOCHEMOTHERAPY INDUCTION
    Castro-gomez, A. J.
    Lopez-Guillermo, A.
    Rueda, A.
    Salar, A.
    Rubio-Terres, C.
    VALUE IN HEALTH, 2011, 14 (07) : A446 - A446
  • [50] COST-EFFECTIVENESS OF THE ADDITION OF RITUXIMAB TO FIRST-LINE CHEMOTHERAPY TREATMENT REGIMENS IN PATIENTS WITH ADVANCED FOLLICULAR LYMPHOMA IN THE UK
    Ray, J. A.
    Carr, E.
    Geary, U.
    VALUE IN HEALTH, 2008, 11 (06) : A343 - A343
12345